JP2023531230A5 - - Google Patents
Info
- Publication number
- JP2023531230A5 JP2023531230A5 JP2022579129A JP2022579129A JP2023531230A5 JP 2023531230 A5 JP2023531230 A5 JP 2023531230A5 JP 2022579129 A JP2022579129 A JP 2022579129A JP 2022579129 A JP2022579129 A JP 2022579129A JP 2023531230 A5 JP2023531230 A5 JP 2023531230A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- cdr
- pharmaceutical product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20183251.6 | 2020-06-30 | ||
| EP20183251 | 2020-06-30 | ||
| US202163147485P | 2021-02-09 | 2021-02-09 | |
| US63/147,485 | 2021-02-09 | ||
| PCT/EP2021/068038 WO2022003042A1 (en) | 2020-06-30 | 2021-06-30 | Anti-s100a4 antibodies for the treatment of systemic sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531230A JP2023531230A (ja) | 2023-07-21 |
| JP2023531230A5 true JP2023531230A5 (https=) | 2024-06-28 |
Family
ID=76601225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579129A Pending JP2023531230A (ja) | 2020-06-30 | 2021-06-30 | 全身性硬化症の治療のための抗ｓ１００ａ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230220058A1 (https=) |
| EP (1) | EP4171752A1 (https=) |
| JP (1) | JP2023531230A (https=) |
| CN (1) | CN115867355A (https=) |
| AU (1) | AU2021301244A1 (https=) |
| CA (1) | CA3183062A1 (https=) |
| WO (1) | WO2022003042A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250011405A1 (en) * | 2021-11-19 | 2025-01-09 | Lykera Biomed, S.A. | Treatment and diagnosis of diseases associated to pathogenic fibrosis |
| CN117686722B (zh) * | 2023-12-20 | 2024-08-09 | 内蒙古元牛繁育科技有限公司 | 一种s100a4纳米抗体及其应用 |
| WO2025188905A1 (en) * | 2024-03-08 | 2025-09-12 | The Board Of Regents Of The University Of Texas System | Anti-s100a antibodies and related compositions and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103201290B (zh) * | 2010-06-14 | 2016-09-28 | 莱克拉生物医学股份公司 | S100a4抗体及其治疗用途 |
| UY34887A (es) * | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| GB201219487D0 (en) | 2012-10-30 | 2012-12-12 | Cancer Rec Tech Ltd | Anti-S100A4 antibody molecules and their uses |
| CA3207703A1 (en) * | 2021-02-09 | 2022-08-18 | Jonas Hallen | Anti-s100a4 humanized antibodies, uses and methods |
-
2021
- 2021-06-30 WO PCT/EP2021/068038 patent/WO2022003042A1/en not_active Ceased
- 2021-06-30 JP JP2022579129A patent/JP2023531230A/ja active Pending
- 2021-06-30 EP EP21734366.4A patent/EP4171752A1/en active Pending
- 2021-06-30 US US18/009,821 patent/US20230220058A1/en active Pending
- 2021-06-30 CA CA3183062A patent/CA3183062A1/en active Pending
- 2021-06-30 AU AU2021301244A patent/AU2021301244A1/en active Pending
- 2021-06-30 CN CN202180045596.5A patent/CN115867355A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11512132B2 (en) | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics | |
| US12258411B2 (en) | Anti-CCR8 antibodies and uses thereof | |
| US8168757B2 (en) | PD-1 binding proteins | |
| KR102937285B1 (ko) | 신규 항-pd-l1 항체 | |
| JP7727086B2 (ja) | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用 | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| JP2018502062A (ja) | Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体 | |
| JP2023531230A5 (https=) | ||
| JP2021501566A5 (https=) | ||
| JP6162319B2 (ja) | ヒト化抗ｎ２抗体 | |
| CA3130281A1 (en) | Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies | |
| JP2023531672A (ja) | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JP2024522237A5 (https=) | ||
| CA3207703A1 (en) | Anti-s100a4 humanized antibodies, uses and methods | |
| WO2022057910A1 (en) | Combination therapies targeting c5ar and pd-1/pd-l1 pathways | |
| KR20230162597A (ko) | 안정적인 다중 특이성 분자 및 그 이용 | |
| WO2026041144A1 (zh) | Pd-1激动性抗体及其用途 | |
| HK40005909B (en) | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics | |
| HK40005909A (en) | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics | |
| HK40117648A (zh) | Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途 | |
| TW202214303A (zh) | 用於癌症治療之結合分子 | |
| HK40052157A (en) | Anti-pd-l1 antibody and use thereof |